De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Statistical Analysis
3. Results
3.1. Kidney Transplant-Specific Patient Characteristics
3.2. Graft Function and Postoperative Complications After Kidney Transplantation
3.3. Oncologic Features and Tumor-Specific Patient Characteristics
3.4. Oncologic Outcomes
3.5. Comparison to a Non-Transplant RCC Cohort
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
BMI | Body Mass Index |
CDC | Clavien–Dindo Classification |
CI | Confidence Interval |
CNI | Calcineurin Inhibitors |
CKD | Chronic Kidney Disease |
CIT | Cold Ischemia Time |
ccRCC | Clear Cell Renal Cell Carcinoma |
cN1 | Clinical Nodal Involvement |
DGF | Delayed Graft Function |
ESRD | End-Stage Renal Disease |
GF | Graft Failure |
GS | Graft Survival |
HR | Hazard Ratio |
KT | Kidney Transplantation |
KTRs | Kidney Transplant Recipients |
M1 | Metastatic Disease |
MMF | Mycophenolate Mofetil |
MFS | Metastasis-Free Survival |
OS | Overall Survival |
PSM | Propensity Score Matching |
pRCC | Papillary Renal Cell Carcinoma |
pT | Pathologic Tumor Stage |
RCC | Renal Cell Carcinoma |
RMST | Restricted Mean Survival Time |
SMD | Standard Mean Difference |
TKI | Tyrosine Kinase Inhibitor |
UICC | Union Internationale Contre le Cancer |
References
- Hernández-Gaytán, C.A.; Rodríguez-Covarrubias, F.; Castillejos-Molina, R.A.; Hernández-Porras, A.; Tobia, I.; Dubin, J.M.; Autrán-Gómez, A.M. Urological Cancers and Kidney Transplantation: A Literature Review. Curr. Urol. Rep. 2021, 22, 62. [Google Scholar] [CrossRef] [PubMed]
- Putz, J.; Kestel, V.; Herout, R.; Borkowetz, A.; Leike, S.; Thomas, C.; Baunacke, M. Urogenital Tumors Following Kidney Transplantation—Monocentric Analysis of Incidences and Overview of Urological Preventive Measures. Urologie 2024, 63, 341–350. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Lan, G.-B.; Peng, F.-H.; Xie, X.-B. Cancer Risks in Recipients of Renal Transplants: A Meta-Analysis of Cohort Studies. Oncotarget 2018, 9, 15375–15385. [Google Scholar] [CrossRef] [PubMed]
- Okumi, M.; Inoue, Y.; Miyashita, M.; Ueda, T.; Fujihara, A.; Hongo, F.; Ukimua, O. Genitourinary Malignancies in Kidney Transplant Recipients. Int. J. Urol. 2024, 31, 1321–1329. [Google Scholar] [CrossRef]
- Karami, S.; Yanik, E.L.; Moore, L.E.; Pfeiffer, R.M.; Copeland, G.; Gonsalves, L.; Hernandez, B.Y.; Lynch, C.F.; Pawlish, K.; Engels, E.A. Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States. Am. J. Transplant. 2016, 16, 3479–3489. [Google Scholar] [CrossRef]
- Miao, Y.; Everly, J.J.; Gross, T.G.; Tevar, A.D.; First, M.R.; Alloway, R.R.; Woodle, E.S. De Novo Cancers Arising in Organ Transplant Recipients Are Associated With Adverse Outcomes Compared With the General Population. Transplantation 2009, 87, 1347–1359. [Google Scholar] [CrossRef]
- Hickman, L.A.; Sawinski, D.; Guzzo, T.; Locke, J.E. Urologic Malignancies in Kidney Transplantation. Am. J. Transplant. 2018, 18, 13–22. [Google Scholar] [CrossRef]
- Hubatsch, M.; Peters, R.; Maxeiner, A.; El-Bandar, N.; Weinberger, S.; Friedersdorff, F. Nephron Sparing Surgery in Renal Allograft in Recipients with de Novo Renal Cell Carcinoma: Two Case Reports and Review of the Literature. Urol. Int. 2020, 104, 997–999. [Google Scholar] [CrossRef]
- Clavien, P.A.; Barkun, J.; De Oliveira, M.L.; Vauthey, J.N.; Dindo, D.; Schulick, R.D.; De Santibañes, E.; Pekolj, J.; Slankamenac, K.; Bassi, C.; et al. The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience. Ann. Surg. 2009, 250, 187–196. [Google Scholar] [CrossRef]
- Möller, L.; Stang, A.; Kajüter, H. Epidemiologie des Nierenzellkarzinoms in Deutschland 2019. Onkologie 2023, 29, 565–570. [Google Scholar] [CrossRef]
- Dahle, D.O.; Skauby, M.; Langberg, C.W.; Brabrand, K.; Wessel, N.; Midtvedt, K. Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. Transplantation 2022, 106, e52–e63. [Google Scholar] [CrossRef] [PubMed]
- Crocerossa, F.; Autorino, R.; Derweesh, I.; Carbonara, U.; Cantiello, F.; Damiano, R.; Rubio-Briones, J.; Roupret, M.; Breda, A.; Volpe, A.; et al. Management of Renal Cell Carcinoma in Transplant Kidney: A Systematic Review and Meta-Analysis. Minerva Urol. Nephrol. 2023, 75, 1–16. [Google Scholar] [CrossRef]
- Robinson, S.; Nag, A.; Peticca, B.; Prudencio, T.; Di Carlo, A.; Karhadkar, S. Renal Cell Carcinoma in End-Stage Kidney Disease and the Role of Transplantation. Cancers 2023, 16, 3. [Google Scholar] [CrossRef]
- Minkovich, M.; Wong, R.B.K.; Famure, O.; Li, Y.; Kim, S.J.; Lee, J.Y. Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Trends, Clinical Management & Outcomes. World J. Urol. 2023, 41, 2389–2395. [Google Scholar] [CrossRef] [PubMed]
- Singh-Singh, A.; Vigara, L.A.; Aguilera, A.; Carrasco, D.; Alonso, M.; Amaro, J.M.; Cazorla, J.M.; Villanego, F.; Mazuecos, A.; García, T. Benefits of Routine Screening for Renal Cell Carcinoma of Native Kidney in Renal Transplant Recipients. Transplant. Proc. 2023, 55, 2262–2265. [Google Scholar] [CrossRef]
- Yohannan, B.; Sridhar, A.; Kaur, H.; DeGolovine, A.; Maithel, N. Screening for Renal Cell Carcinoma in Renal Transplant Recipients: A Single-Centre Retrospective Study. BMJ Open 2023, 13, e071658. [Google Scholar] [CrossRef] [PubMed]
- Tao, Y.; Wang, J.; Peng, Y.; Zhou, J. Renal Cell Carcinoma of the Native Kidney in Renal Transplant Recipients: Case Report and Literature Review. Front. Oncol. 2025, 15, 1536411. [Google Scholar] [CrossRef]
- Aveta, A.; Iossa, V.; Spena, G.; Conforti, P.; Pagano, G.; Dinacci, F.; Verze, P.; Manfredi, C.; Ferro, M.; Lasorsa, F.; et al. Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review. Life 2024, 14, 450. [Google Scholar] [CrossRef]
- Végsö, G.; Toronyi, É.; Hajdu, M.; Piros, L.; Görög, D.; Deák, P.A.; Doros, A.; Péter, A.; Langer, R.M. Renal Cell Carcinoma of the Native Kidney: A Frequent Tumor After Kidney Transplantation With Favorable Prognosis in Case of Early Diagnosis. Transplant. Proc. 2011, 43, 1261–1263. [Google Scholar] [CrossRef]
- Moris, D.; Kakavia, K.; Argyrou, C.; Garbis, N.; Bokos, J.; Vernadakis, S.; Diles, K.; Sotirchos, G.; Boletis, J.; Zavos, G. De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience. Anticancer Res. 2017, 37, 773–779. [Google Scholar] [CrossRef]
- Dhakal, P.; Giri, S.; Siwakoti, K.; Rayamajhi, S.; Bhatt, V.R. Renal Cancer in Recipients of Kidney Transplant. Rare Tumors 2017, 9, 9–13. [Google Scholar] [CrossRef] [PubMed]
- Tsaur, I.; Obermüller, N.; Jonas, D.; Blaheta, R.; Juengel, E.; Scheuermann, E.; Kachel, H.; Karalis, A.; Probst, M. De Novo Renal Cell Carcinoma of Native and Graft Kidneys in Renal Transplant Recipients. BJU Int. 2011, 108, 229–234. [Google Scholar] [CrossRef] [PubMed]
- Ficarra, V.; Mosca, A.; Rossanese, M.; Subba, E.; Giannarini, G. Is Active Surveillance an Option for Metachronous Metastatic Renal Cell Carcinoma? Ann. Transl. Med. 2019, 7, 84. [Google Scholar] [CrossRef] [PubMed]
- Breda, A.; Budde, K.; Figueiredo, A.; García, E.L.; Olsburgh, J.; Regele, H.; Zakri, R.H. Eau Guidelines on Renal Transplantation; EAU Guidelines Office: Arnhem, The Netherlands, 2024. [Google Scholar]
- Tufano, A.; Drudi, F.M.; Angelini, F.; Polito, E.; Martino, M.; Granata, A.; Di Pierro, G.B.; Kutrolli, E.; Sampalmieri, M.; Canale, V.; et al. Contrast-Enhanced Ultrasound (CEUS) in the Evaluation of Renal Masses with Histopathological Validation—Results from a Prospective Single-Center Study. Diagnostics 2022, 12, 1209. [Google Scholar] [CrossRef]
- Cui, X.; Yan, C.; Xu, Y.; Li, D.; Guo, M.; Sun, L.; Zhu, Z. Allograft Rejection Following Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Safety Analysis from a Literature Review and a Pharmacovigilance System. Cancer Med. 2023, 12, 5181–5194. [Google Scholar] [CrossRef]
- Motzer, R.J.; Hutson, T.E.; Cella, D.; Reeves, J.; Hawkins, R.; Guo, J.; Nathan, P.; Staehler, M.; De Souza, P.; Merchan, J.R.; et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med. 2013, 369, 722–731. [Google Scholar] [CrossRef]
- Suso-Palau, D.; Chavarriaga, J.; Usubillaga, F.; Asprilla, J.; Micolta, L.; Urrego, M. Metastatic Renal Cell Carcinoma of the Native Kidney in a Renal Transplant Recipient: Revisiting the Era of Tyrosine Kinase Inhibitors—Case Report. Urol. Case Rep. 2022, 43, 102082. [Google Scholar] [CrossRef]
- Studentova, H.; Spisarova, M.; Kopova, A.; Zemankova, A.; Melichar, B.; Student, V. The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Cancers 2023, 15, 3855. [Google Scholar] [CrossRef]
- Krisl, J.C.; Doan, V.P. Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. Am. J. Transplant. 2017, 17, 1974–1991. [Google Scholar] [CrossRef]
- Venkatachalam, K.; Malone, A.F.; Heady, B.; Santos, R.D.; Alhamad, T. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation 2020, 104, 1041–1047. [Google Scholar] [CrossRef]
- Andras, I.; Pecoraro, A.; Telecan, T.; Piana, A.; Boissier, R.; Hevia, V.; Prudhomme, T.; Amparore, D.; Bertolo, R.; Carbonara, U.; et al. How to Manage Renal Masses in Kidney Transplant Recipients? A Collaborative Review by the EAU-YAU Kidney Transplantation and Renal Cancer Working Groups. Actas Urológicas Españolas 2023, 47, 621–630. [Google Scholar] [CrossRef] [PubMed]
Characteristic | RCC (n = 50) |
---|---|
Age at KT (years) | 56.5 (45.25–63.25) |
BMI at KT (kg/m2) | 23.9 (22.61–27.29) |
Gender, n (%) | |
Male | 35 (70) |
Female | 15 (30) |
Donor age (years) | 54 (45–62) |
Donor gender, n (%) | |
Male | 24 (48) |
Female | 24 (48) |
Unknown | 2 (4) |
Living donor, n (%) | 12 (24) |
Overall HLA mismatches, n (%) | |
0 | 7 (14) |
1 | 3 (6) |
2 | 14 (28) |
3 | 8 (16) |
4 | 9 (18) |
≥5 | 6 (12) |
Unknown | 3 (6) |
HLA-A mismatches, n (%) | |
0 | 19 (38) |
1 | 20 (40) |
2 | 8 (16) |
HLA-B mismatches, n (%) | |
0 | 15 (30) |
1 | 20 (40) |
2 | 12 (24) |
HLA-DR mismatches, n (%) | |
0 | 15 (30) |
1 | 19 (38) |
2 | 13 (26) |
Panel reactive antibodies, n (%) | |
0 | 36 (72) |
1–20% | 1 (2) |
21–50% | 1 (2) |
Unknown | 12 (24) |
Location of renal transplant, n (%) | |
Left iliac fossa | 24 (48) |
Right iliac fossa | 26 (52) |
Underlying disease for CKD, n (%) | |
IgA nephropathy | 8 (16) |
Idiopathic membranous glomerulonephritis | 6 (12) |
FSGS | 6 (12) |
Diabetic nephropathy | 4 (8) |
ADPKD | 1 (2) |
Hypertensive kidney disease | 4 (8) |
Nephrosclerosis | 5 (10) |
Renal atrophy | 5 (10) |
Tubulointerstitial nephritis | 4 (8) |
Other | 7 (14) |
Induction immunosuppression | |
Basiliximab | 42 (84) |
Janus kinase inhibitor | 1 (2) |
Thymoglobuline | 1 (2) |
Infliximab | 1 (2) |
Unknown | 4 (8) |
Maintenance immunosuppression, n (%) | |
Tacrolimus | 32 (64) |
MMF | 47 (94) |
Ciclosporin | 10 (20) |
Corticosteroids | 26 (52) |
Waiting time for KT (months) | 36.5 (10.75–77.25) |
Time of dialysis (months) | 62.5 (21.5–88.75) |
Remaining diuresis prior KT (ml) | 300 (0–1500) |
Type of dialysis, n (%) | |
Hemodialysis | 46 (92) |
Peritoneal dialysis | 3 (6) |
CIT (min) | 667 (187.25–989.75) |
Operative time (min) | 216 (181.25–251.25) |
Major complication, n (%); (CDC ≥ 3, 30 d) | 5 (10) |
Delayed graft function, n (%) | 20 (40) |
Rejection, n (%) | 15 (30) |
Creatinine level (mg/dL) | |
Preoperative | 7.1 (5.86–9.24) |
6 months post KT | 1.5 (1.22–2.03) |
1 year post KT | 1.5 (1.10–2.00) |
3 years post KT | 1.6 (1.14–2.00) |
5 years post KT | 1.6 (1.20–2.04) |
Graft failure | 22 (44) |
Death censored graft failure, n (%) | 16 (32) |
Cause of graft failure, n (%) | |
Chronic rejection | 5 (10.9) |
Tumor | 2 (4.3) |
Nephrosclerosis | 1 (2.2) |
Primary non function | 1 (2.2) |
Acute kidney injury | 1 (2.2) |
Death with functioning graft | 6 (13) |
CNI toxicity | 1 (2.2) |
Unknown | 2 (4.3) |
Transplant nephrectomy, n (%) | 3 (9.1) |
Follow-up after KT (months) | 139 (88.25–175) |
Characteristic | RCC (n = 50) |
---|---|
Age at tumor diagnosis (years) | 58.5 (51–68.25) |
Time from KT to tumor (months) | 47 (13.25–83.50) |
Prior malignancy, n (%) | 11 (22) |
History of smoking, n (%) | 18 (36) |
Hematuria, n (%) | 3 (6) |
Tumor location, n (%) | |
Native kidney | 46 (92) |
Kidney transplant | 4 (8) |
Unilateral | 48 (96) |
Bilateral | 2 (4) |
Tumor number, n (%) | |
1 | 45 (90) |
2 | 5 (10) |
Histology, n (%) | |
ccRCC | 21 (42) |
pRCC | 21 (42) |
ccRCC + pRCC | 2 (4) |
Others | 4 (8) |
Unknown | 2 (4) |
UICC stage, n (%) | |
I | 37 (74) |
III | 6 (12) |
IV | 7 (14) |
pT-Stadium, n (%) | |
1a | 28 (56) |
1b | 9 (18) |
3a | 5 (10) |
3b | 1 (2) |
3c | 1 (2) |
Unknown | 6 (12) |
Grading, n (%) | |
G1 | 10 (20) |
G2 | 23 (46) |
G3 | 7 (14) |
G4 | 1 (2) |
Unknown/unclear | 9 (18) |
Clinical positive lymph nodes, n (%) | 8 (16) |
Synchronous metastases (M1), n (%) | 7 (14) |
Pulmonary | 6 (85.7) |
Lymphonodal | 5 (71.4) |
Bone | 4 (57.1) |
Hepatic | 1 (14.3) |
IMDC low risk | 3 (42.9) |
IMDC high risk | 4 (57.1) |
Follow-up after tumor diagnosis (months) | 60.5 (21–131.75) |
Characteristic | RCC (n = 50) |
---|---|
Therapy—non-metastatic RCC (M0), n (%) | |
None | 1 (2.3%) |
Native nephrectomy | 36 (83.7) |
Native nephrectomy + TKI | 1 (2.3) |
Transplant nephrectomy | 3 (7) |
Partial transplant nephrectomy | 1 (2.3) |
Local ablation | 1 (2.3) |
Therapy—synchronous metastatic RCC (M1), n (%) | |
Native nephrectomy | 2 (28.6) |
TKI | 4 (57.1) |
Native nephrectomy + TKI | 1 (14.3) |
R-Status, n (%) | |
R0 | 38 (76) |
R1 | 2 (4) |
Recurrence, n (%) | 4 (8) |
Contralateral native kidney | 3 (75) |
Contralateral native kidney and graft | 1 (25) |
Time to recurrence (months) | 49.5 (31.25–133.75) |
Recurrence-free survival | Median not reached |
3-year RFS | 94% |
5-year RFS | 90% |
Metachronous metastasis, n (%) | 4 (8%) |
Pulmonary | 2 (50%) |
Lymphonodal | 3 (75%) |
Bone | 1 (25%) |
Retroperitoneal | 1 (25%) |
Time to metastases (months) | 58 (31.25–143.25) |
Metastasis-free survival | Median not reached |
3-year MFS | 94% |
5-year MFS | 94% |
Death, n (%) | 14 (28%) |
Cause of death, n (%) | |
RCC | 3 (6%) |
Other malignancy | 2 (4.1%) |
Pneumonia | 1 (2%) |
Sepsis | 1 (2%) |
Cardiac arrest | 1 (2%) |
Unknown | 6 (12.2%) |
Overall survival—whole cohort (months) | 199 (CI 103–295) |
3-year OS | 85% |
5-year OS | 72% |
OS with synchronous metastases (months) | 14 (CI 0–28) |
OS with metachronous metastases (months) | 61 (CI 0–126) |
Characteristic | Non-KTR with RCC (n = 34) | KTR with RCC (n = 34) | SMD | p * |
---|---|---|---|---|
Age (years) | 58 (50.75–65) | 56.5 (47–66.5) | 0.05 | 0.91 |
Histology, n (%) | <0.001 | 1.0 | ||
ccRCC | 18 (52.9) | 18 (52.9) | ||
pRCC | 16 (47.1) | 16 (47.1) | ||
pT-Status, n (%) | 0.26 | 0.76 | ||
1a | 24 (70.6) | 22 (64.7) | ||
1b | 7 (20.6) | 8 (23.5) | ||
3a | 3 (8.8) | 3 (8.8) | ||
3b | 0 | 1 (2.9) | ||
Grading, n (%) | 0.11 | 0.34 | ||
G1 | 7 (20.6) | 8 (23.5) | ||
G2 | 26 (76.5) | 22 (64.7) | ||
G3 | 1 (2.9) | 4 (11.8) | ||
Metachronous metastases, n (%) | 3 (10) | 4 (11.8) | 0.82 | |
Metastasis-free survival | Median not reached | Median not reached | 0.61 | |
3-year | 92% | 93% | ||
5-year | 92% | 93% | ||
Restricted mean metastasis-free survival time (months) | ||||
5-year | 57.8 (CI 54.5–61.1) | 58 (CI 55.2–60.7) | 0.94 | |
10-year | 113.1 (CI 103.8–122.4) | 111.9 (CI 103–120.8) | 0.86 | |
Death, n (%) | 5 (16.1) | 6 (17.6) | 0.87 | |
Overall survival (months) | Median not reached | 199 (CI 60–338) | 0.72 | |
3-year | 100% | 96% | ||
5-year | 96% | 84% | ||
Restricted mean overall survival time (months) | ||||
5-year | 60 (CI 60–60) | 58.6 (CI 56.7–60.6) | 0.18 | |
10-year | 114 (CI 108–120.1) | 108.6 (CI 99–118.2) | 0.35 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schmidt, J.; Lehnert, M.; Lichy, I.; Plage, H.; Jeutner, J.; Kurz, L.; Ralla, B.; Lerchbaumer, M.H.; Schlomm, T.; Friedersdorff, F.; et al. De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges. Cancers 2025, 17, 2200. https://doi.org/10.3390/cancers17132200
Schmidt J, Lehnert M, Lichy I, Plage H, Jeutner J, Kurz L, Ralla B, Lerchbaumer MH, Schlomm T, Friedersdorff F, et al. De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges. Cancers. 2025; 17(13):2200. https://doi.org/10.3390/cancers17132200
Chicago/Turabian StyleSchmidt, Jacob, Malte Lehnert, Isabel Lichy, Henning Plage, Jonathan Jeutner, Lukas Kurz, Bernhard Ralla, Markus H. Lerchbaumer, Thorsten Schlomm, Frank Friedersdorff, and et al. 2025. "De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges" Cancers 17, no. 13: 2200. https://doi.org/10.3390/cancers17132200
APA StyleSchmidt, J., Lehnert, M., Lichy, I., Plage, H., Jeutner, J., Kurz, L., Ralla, B., Lerchbaumer, M. H., Schlomm, T., Friedersdorff, F., Maxeiner, A., & Peters, R. (2025). De Novo Renal Cell Carcinoma in Kidney Transplant Recipients: Incidence, Outcomes, and Therapeutic Challenges. Cancers, 17(13), 2200. https://doi.org/10.3390/cancers17132200